Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development

Nature Medicine

Volumn 21, Issue 1, 2015, Pages 37-46

  Kang, Hyun Mi ^a   Ahn, Seon Ho ^a,f   Choi, Peter ^a   Ko, Yi An ^a   Han, Seung Hyeok ^a   Chinga, Frank ^a   Park, Ae Seo Deok ^a   Tao, Jianling ^a,g   Sharma, Kumar ^b   Pullman, James ^c   Bottinger, Erwin P ^d   Goldberg, Ira J ^e   Susztak, Katalin ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f Wonkwang University   (South Korea)

^g PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; FATTY ACID; TRANSCRIPTOME; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEATH; CELL DEDIFFERENTIATION; DISEASE COURSE; ENERGY RESOURCE; FATTY ACID OXIDATION; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE EPITHELIUM; LIPID STORAGE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; EPITHELIUM CELL; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; INFLAMMATION; KIDNEY DISEASE; KIDNEY TUBULE; METABOLISM; OXIDATION REDUCTION REACTION; PATHOLOGY; SIGNAL TRANSDUCTION;

MUS;

ANIMALS; EPITHELIAL CELLS; FATTY ACIDS; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; INFLAMMATION; KIDNEY DISEASES; KIDNEY TUBULES; MICE; OXIDATION-REDUCTION; SIGNAL TRANSDUCTION;

EID: 84925284486     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3762     Document Type: Article

References (40)

1. Brosius, F.C. III et al. Mouse models of diabetic nephropathy. J. Am. Soc. Nephrol. 20, 2503-2512 (2009).
2. Nath, K.A., Salahudeen, A.K., Clark, E.C., Hostetter, M.K. & Hostetter, T.H. Role of cellular metabolites in progressive renal injury. Kidney Int. Suppl. 38, S109-S113 (1992).
3. Humphreys, B.D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010).
4. Zeisberg, M. et al. BMP-7 counteracts TGF-β1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat. Med. 9, 964-968 (2003).
5. Bielesz, B. et al. Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans. J. Clin. Invest. 120, 4040-4054 (2010).
6. Kato, H. et al. Wnt/β-catenin pathway in podocytes integrates cell adhesion, differentiation, and survival. J. Biol. Chem. 286, 26003-26015 (2011).
7. Fabian, S.L. et al. Hedgehog-Gli pathway activation during kidney fibrosis. Am. J. Pathol. 180, 1441-1453 (2012).
8. Böttinger, E.P. & Bitzer, M. TGF-β signaling in renal disease. J. Am. Soc. Nephrol. 13, 2600-2610 (2002).
9. DeBerardinis, R.J. & Thompson, C.B. Cellular metabolism and disease: what do metabolic outliers teach us? Cell 148, 1132-1144 (2012).
10. Oldfield, M.D. et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J. Clin. Invest. 108, 1853-1863 (2001).
11. Rowe, I. et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat. Med. 19, 488-493 (2013).
12. Susztak, K., Ciccone, E., McCue, P., Sharma, K. & Bottinger, E.P. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med. 2, e45 (2005).
13. Schug, T.T. & Li, X. Sirtuin 1 in lipid metabolism and obesity. Ann. Med. 43, 198-211 (2011).
14. Tran, M. et al. PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J. Clin. Invest. 121, 4003-4014 (2011).
15. Proctor, G. et al. Regulation of renal fatty acid and cholesterol metabolism, inflammation, and fibrosis in Akita and OVE26 mice with type 1 diabetes. Diabetes 55, 2502-2509 (2006).
16. Chau, B.N. et al. MicroRNA-21 promotes fibrosis of the kidney by silencing metabolic pathways. Sci. Transl. Med. 4, 121ra118 (2012).
17. Portilla, D. et al. Metabolomic study of cisplatin-induced nephrotoxicity. Kidney Int. 69, 2194-2204 (2006).
18. Herman-Edelstein, M., Scherzer, P., Tobar, A., Levi, M. & Gafter, U. Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy. J. Lipid Res. 55, 561-572 (2014).
19. Li, S. et al. Transgenic expression of proximal tubule peroxisome proliferator-activated receptor-α in mice confers protection during acute kidney injury. Kidney Int. 76, 1049-1062 (2009).
20. Declèves, A.E. et al. Regulation of lipid accumulation by AMP-activated kinase [corrected] in high fat diet-induced kidney injury. Kidney Int. 85, 611-623 (2014).
21. Woroniecka, K.I. et al. Transcriptome analysis of human diabetic kidney disease. Diabetes 60, 2354-2369 (2011).
22. Si, H. et al. Human and murine kidneys show gender-and species-specific gene expression differences in response to injury. PLoS ONE 4, e4802 (2009).
23. Vielhauer, V. et al. CCR1 blockade reduces interstitial inflammation and fibrosis in mice with glomerulosclerosis and nephrotic syndrome. Kidney Int. 66, 2264-2278 (2004).
24. Goldberg, I.J., Trent, C.M. & Schulze, P.C. Lipid metabolism and toxicity in the heart. Cell Metab. 15, 805-812 (2012).
25. Zavadil, J., Cermak, L., Soto-Nieves, N. & Bottinger, E.P. Integration of TGF-β/Smad and Jagged1/Notch signalling in epithelial-to-mesenchymal transition. EMBO J. 23, 1155-1165 (2004).
26. Kim, S.W. et al. Chromatin and transcriptional signatures for Nodal signaling during endoderm formation in hESCs. Dev. Biol. 357, 492-504 (2011).
27. Ko, Y.A. et al. Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development. Genome Biol. 14, R108 (2013).
28. Kuhajda, F.P. et al. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA 97, 3450-3454 (2000).
29. Wanner, C., Drechsler, C. & Krane, V. Lipid metabolism in chronic kidney disease: the role of statins in cardiovascular risk. J. Ren. Nutr. 17, 75-78 (2007).
30. Kovesdy, C.P., Anderson, J.E. & Kalantar-Zadeh, K. Inverse association between lipid levels and mortality in men with chronic kidney disease who are not yet on dialysis: effects of case mix and the malnutrition-inflammation-cachexia syndrome. J. Am. Soc. Nephrol. 18, 304-311 (2007).
31. Khan, S. et al. Lipotoxic disruption of NHE1 interaction with PI4, 5P2 expedites proximal tubule apoptosis. J. Clin. Invest. 124, 1057-1068 (2014).
32. Meyer, C., Nadkarni, V., Stumvoll, M. & Gerich, J. Human kidney free fatty acid and glucose uptake: evidence for a renal glucose-fatty acid cycle. Am. J. Physiol. 273, E650-E654 (1997).
33. Li, B. et al. Fructose-1, 6-bisphosphatase opposes renal carcinoma progression. Nature 513, 251-255 (2014).
34. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 499, 43-49 (2013).
35. Yadav, H. et al. Protection from obesity and diabetes by blockade of TGF-β/Smad3 signaling. Cell Metab. 14, 67-79 (2011).
36. Dugan, L.L. et al. AMPK dysregulation promotes diabetes-related reduction of superoxide and mitochondrial function. J. Clin. Invest. 123, 4888-4899 (2013).
37. Samudio, I. et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J. Clin. Invest. 120, 142-156 (2010).
38. Jun, M. et al. Effects of fibrates in kidney disease: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 60, 2061-2071 (2012).
39. Davis, T.M. et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 54, 280-290 (2011).
40. Ansquer, J.C. et al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS). Am. J. Kidney Dis. 45, 485-493 (2005).